Andyforce Appoints RNA Expert Professor Roger Kornberg as Internal Director

Granting Stock Options and Focusing on New Drug Development Capabilities

[Asia Economy Reporter Hyungsoo Park] AndyForce is accelerating its new drug development business by granting stock options following the appointment of Nobel Chemistry Prize laureate Professor Roger Kornberg as an inside director.

On the 27th, AndyForce announced that it will grant Professor Roger Kornberg stock options amounting to 2% (1 million shares) of the total issued shares.

AndyForce plans to focus all its capabilities on new drug development by granting stock options to Professor Roger Kornberg. Professor Roger Kornberg was awarded the Nobel Prize in Chemistry for discovering various enzyme proteins involved in the transcription process, a biomedical process that regulates most human gene expression, and for elucidating the structure of transcription-related protein complexes at the atomic level. With the outbreak of the novel coronavirus disease (COVID-19), he has been working with members of the World Laureates Association (WLA) to develop treatments for the COVID-19 virus.

A company official stated, “Typically, granting stock options means providing incentives to retain key personnel long-term,” and explained, “By granting stock options to Professor Roger Kornberg, AndyForce can create long-term synergy with key personnel in the new drug development business.”

He added, “Recently, with the new pipeline based on siRNA technology entering the development of treatments for lung cancer and viral infections such as COVID-19, greater synergy with Professor Roger Kornberg is expected.”

This content was produced with the assistance of AI translation services.